Penn Medicine Provider
Diabetes
Jorge Jo Kamimoto, MD
4.9
(58)
Accepting new patients
Penn Rodebaugh Diabetes Center

About me

  • Assistant Professor of Clinical Medicine (Endocrinology, Diabetes and Metabolism)

Education and training

  • Residency: University of Arkansas for Medical Sciences
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

58 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
gave me good explanation of medicine for me that may possibly work for me
February 2025
5.0
5.0
he was very nice and informative
February 2025
5.0
5.0
if anyone needs a good thorough doctor
November 2024
5.0
5.0
he took the time to see me

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.
Dr. Jo Kamimoto is a Penn Medicine physician.

Qualifications and experience

My research

Kudva YC, Henderson RJ, Kanapka LG, Weinstock RS, Rickels MR, Pratley RE, Chaytor N, Janess K, Desjardins D, Pattan V, Peleckis AJ, Casu A, Rizvi SR, Bzdick S, Whitaker KJ, Jo Kamimoto JL, Miller K, Kollman C, Beck RW. Automated Insulin Delivery in Older Adults with Type 1 Diabetes , NEJM Evid: 2025


Kudva YC, Henderson RJ, Kanapka LG, Weinstock RS, Rickels MR, Pratley RE, Chaytor N, Janess K, Desjardins D, Pattan V, Peleckis AJ, Casu A, Rizvi SR, Bzdick S, Whitaker KJ, Kamimoto JLJ, Miller K, Kollman C, Beck RW; AIDE study group. Automated Insulin Delivery in Elderly with Type 1 Diabetes: A Prespecified Analysis of the Extension Phase , Diabetes Technol Ther: 2025


Kamimoto JLJ, Li Z, Gal RL, Castle JR, Doyle FJ 3rd, Jacobs PG, Martin CK, Beck RW, Calhoun P, Riddell MC, Rickels MR. Effect of Impaired Awareness of Hypoglycemia on Glucose Decline During and After Exercise in the T1DEXI Study , J Clin Endocrinol Metab, 109: 2024,2233-2241


KUDVA, YOGISH C., HENDERSON, ROBERT, KANAPKA, LAUREN, WEINSTOCK, RUTH S., RICKELS, MICHAEL R., PRATLEY, RICHARD E., CHAYTOR, NAOMI, JANESS, KAMILLE, DESJARDINS, DONNA, PATTAN, VISHWANATH, PELECKIS, AMY, CASU, ANNA, RAZA RIZVI, SHAFAQ, BZDICK, SUZAN, WHITAKER, KERI J., JO KAMIMOTO, JORGE L., MILLER, KELLEE, BECK, ROY 144-OR: A Randomized Clinical Trial of Automated Insulin Delivery in Elderly with Type 1 Diabetes , Diabetes, 73(Supplement_1): 2024


Jo Kamimoto JL, Flood JJ. Systemic Thyroid Dysfunction in Graves Disease , Int Ophthalmol Clin, 63: 2023,55-63


Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo, Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. , Amer J Hematol, 92(8): 2017


Jorge Jo Kamimoto, MD, Sandra Susanibar, MD, Meera Mohan, MD, Piroon Jenjaroenpun, PhD, Krishnan Gayathri, MD, Juan Carlos Rico, MD, Mary J Burgess, MD, Ruslana Tytarenko, MS, Nicole Emery, BS M(ASCP), Eric Rosenbaum, MD, MPH, Brian Walker, PhD, Intawat Nookaew, PhD, Atul Kothari, MD Severity and Clinical Outcomes of Clostridium difficile Infection Based on Toxin B Assay Results , Infectious Disease Society of America National Meeting - IDWEEK 2018 San Francisco , California : 2018


Johnsrud AJ, Johnsrud JJ, Susanibar SA, Jo Kamimoto J, Kothari A, Burgess M, Van Rhee F, Rico JC. Infectious and immunological sequelae of daratumumab in multiple myeloma. , British Journal of Haematology , 185(1): 2019,187-189


Schinke C, Hoering A, Wang H, Carlton V, Thanendrarajan S, Deshpande, S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Kamimoto JJ, Grazziutti M, van Rhee F, Zangari M, Insuasti-, Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, and, Morgan GJ. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. , Haematologica., 102(8): 2017,e313-e316


Johnsrud AJ, Susanibar-Adaniya SA, Jo-Kamimoto J, Johnsrud JJ, Kothari, A, Burgess M, Schinke C, Thanendrarajan S, Zangari M, Davies F, Morgan, G, Van Rhee F, Rico JC. Infectious and immunologic complications of Daratumumab containing therapy for Multiple Myeloma. , American Society of Hematology, Atlanta, GA.: 2017